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Objectives This study examined the effect of a single dose of cyclosporine administered at the time of reperfusion on left
ventricular (LV) remodeling and function by cardiac magnetic resonance 5 days and 6 months after myocardial
infarction.
Background In a human study, administration of cyclosporine at the time of acute reperfusion was associated with a smaller
infarct size.
Methods Twenty-eight patients of the original cyclosporine study had an acute (at 5 days) and a follow-up (at 6 months)
cardiac magnetic resonance study to determine LV volumes, mass, ejection fraction, myocardial wall thickness
in infarcted and remote noninfarcted myocardium, and infarct size.
Results There was a persistent reduction in infarct size at 6 months in the cyclosporine group compared with the control
group of patients (29  15 g vs. 38  14 g; p  0.04). There was a significant reduction of LV end-systolic vol-
ume (and a trend for LV end-diastolic volume; p  0.07) in the cyclosporine group compared with the control
group, both at 5 days and 6 months after infarction. There was no significant difference between the 2 groups in
either global LV mass or regional wall thickness of the remote noninfarcted myocardium at 5 days or 6 months.
Attenuation of LV dilation and improvement of LV ejection fraction by cyclosporine at 6 months were correlated
with infarct size reduction.
Conclusions Cyclosporine used at the moment of acute myocardial infarction reperfusion persistently reduces infarct size and
does not have a detrimental effect on LV remodeling. These results are preliminary and must be supported by
further studies. (Ciclosporin A and Acute Myocardial Infarction; NCT00403728) (J Am Coll Cardiol 2010;55:
1200–5) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.052C
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lecently, we showed that the administration of cyclosporine at
he time of reperfusion in patients undergoing percutaneous
oronary intervention for an acute myocardial infarction
AMI) was associated with a reduction in infarct size (1).
The rationale of this proof-of-concept study was that
yclosporine is a potent inhibitor of the opening of the
itochondrial permeability transition pore, which plays a
rucial role in lethal myocardial reperfusion injury (2–5).
rom the *Hospices Civils de Lyon, Université Claude Bernard Lyon, Lyon, France;
Inserm U886, Lyon, France; ‡Inserm U661, Montpellier, France; and the §Hopital
rnaud de Villeneuve, Université de Montpellier I and II, Montpellier, France. Dr.
ewton was supported by a research grant from the French Federation of Cardiology
Fédération Française de Cardiologie).v
Manuscript received June 24, 2009; revised manuscript received September 16,
009, accepted October 20, 2009.yclosporine inhibits mitochondrial permeability transition
ore opening via its binding to the peptidylprolyl isomerase
yclophilin D located in the mitochondrial matrix (6).
See page 1206
However, cyclosporine is not specific for cyclophilin D
nd also forms a complex with cytosolic cyclophilin A that
nhibits the calcium-activated protein phosphatase cal-
ineurin. The calcineurin-dependent pathway seems to be
rucial for the compensatory myocardial hypertrophy of the
emote noninfarcted myocardium during the early post-
MI remodeling stage. Animal studies have found that
ong-term daily administration of cyclosporine can alter left
entricular (LV) remodeling after AMI and favor the
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March 23, 2010:1200–5 Cyclosporine and LV Remodelingevelopment of heart failure (7,8). There are no published data
howing a detrimental effect of a single dose of cyclosporine at
he time of reperfusion on LV remodeling, although a single
ose of cyclosporine is unlikely to exert any long-term
etrimental effect on LV remodeling.
The aim of the present study was therefore to assess the
afety and efficacy of a single dose of cyclosporine admin-
stered at the time of reperfusion using cardiac magnetic
esonance (CMR) at 5 days and at 6 months after AMI in
subset of 28 patients of our original cyclosporine study (1).
ethods
ll patients of this study were part of the original cyclo-
porine study, previously reported. The study protocol,
etting, and inclusion and exclusion criteria were also
reviously reported (1).
The ethics committee of our institution approved the
rial, and all subjects gave written informed consent before
nclusion in the study.
Because of limited access to magnetic resonance imaging
acilities, only a subgroup of patients underwent the acute
nd follow-up CMR studies.
agnetic resonance imaging protocol and CMR analysis.
MR studies were performed on a 1.5-T whole-body scanner
Magnetom Avanto, Siemens Medical Solutions, Erlangen,
ermany). LV function, volumes, and mass at rest and infarct
ize were assessed as previously described (1) (Fig. 1).
Figure 1 Extensive Anteroseptal Infarction in a 69-Year-Old Ma
Acute (top) and 6-month follow-up (bottom) short-axis images using cine magnetic
sponding late gadolinium-enhanced images (right panels). Contrast-enhanced mag
lar anteroseptal wall (arrows) at both study times with small central hypointense s
imaging, significant thinning of the left ventricular anteroseptal wall between baseltatistical analysis. Summary
alues are expressed as mean 
D. Categorical data were com-
ared by using the Fisher exact
est and continuous variables
ere compared by using Student
test. Two-way analysis of vari-
nce was used to assess differ-
nces between the means of con-
inuous variables at 5 days and 6
onths between the 2 groups.
hen significant, differences
ithin and between each group
ere tested by a post hoc analysis
sing the Bonferroni correction
or multiple comparisons. We performed an analysis of
ovariance to test for equality of the slopes of the regression
f infarct size defined by late gadolinium enhancement
agnetic resonance imaging at 6 months on the area at risk
n the cyclosporine and control groups. Simple linear re-
ression analysis was used to assess the correlation between
nfarct size at 6 months and left ventricular ejection fraction
LVEF) and cavity volumes.
A computerized statistical program (SPSS for Windows,
ersion 12.0, SPSS Inc., Chicago, Illinois) was used for all
nalyses. All tests were 2-sided. The p values 0.05 were
onsidered statistically significant.
ntrol)
ance at end diastole (left panels), end systole (middle panels), and their corre-
resonance imaging shows complete transmural enhancement of the left ventricu-
f microvascular obstruction (red asterisk). On cine magnetic resonance
d 6 months can be observed.
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tudy population. Characteristics of the whole study pop-
lation at first admission were previously reported (1).
wenty-eight (13 in the control and 15 in the cyclosporine
roup) of 58 patients included in the initial study had a
MR study done at 5 days and 6 months. In the CMR
ubpopulation of patients, there was no significant differ-
nce between the 2 groups for comorbidities, LV and
oronary angiography characteristics at admission, or med-
cal treatment at 6 months (Table 1).
MR results. INFARCT SIZE. At 5 days, infarct size in the
yclosporine group averaged 34  14 g versus 48  24 g in
he control group (p  0.03). There was a significant 15%
o 20% shrinkage of the infarcted tissue area in the 2 groups
etween the 2 CMR studies. The initial significant differ-
nce between the 2 groups was maintained at 6 months,
ith the infarct size averaging 29 15 g in the cyclosporine
roup and 38  14 g in the control group (p  0.04), as
hown in Table 2.
The infarct size at 6 months correlated with area at risk as
easured by LV angiography at admission (Fig. 2). Impor-
antly most data points for the cyclosporine group fell below
he control regression line, confirming that infarct size
eduction by cyclosporine was independent of the size of the
rea at risk.
V volumes and function at 5 days and 6 months. At 5
ays, there were significantly lower left ventricular end-
tudy Population Baseline CharacteristicsTable 1 Study Population Baseline Characteristics
Cyclosporine
(n  15)
Control
(n  13) p Value
Age, yrs 60 10 63 12 0.45
Sex, M/F 12/3 8/5 0.38
BMI, kg/m2 27 4 25 4 0.44
Hypertension 4/15 4/13 1.0
Smokers 8/15 7/13 1.0
Dyslipidemia 6/15 4/13 0.41
Diabetes 4/15 3/13 0.67
LV and coronary angiography
Infarct-related artery 0.46
LAD 6 (40%) 7 (54%)
RCA 9 (60%) 6 (46%)
LVEF, % 49 9 53 11 0.40
ACS, % 41 15 39 8 0.17
Ischemia time, min 379 201 290 129 0.31
Treatment at 6 months after
AMI, %
Aspirin 15/15 13/13 1.0
Clopidogrel 15/15 13/13 1.0
ACE inhibitors 13/15 10/13 0.64
Beta-blockers 13/15 11/13 1.0
Statins 14/15 12/13 1.0
alues are expressed as mean  SD, n/N, or n (%).
ACE  angiotensin-converting enzyme; ACS  abnormally contracting segments; AMI  acute
yocardial infarction; BMI  body mass index; LAD  left anterior descending coronary artery;
V  left ventricular; LVEF  left ventricular ejection fraction; RCA  right coronary artery.iastolic volume (LVEDV) and left ventricular end-systolicolume (LVESV) in the cyclosporine compared with the
ontrol group (Table 2). There was no significant difference
n LVEF between the 2 groups.
At 6 months, we observed a lower LVESV in the
yclosporine group compared with the control group. Re-
arding the LVEDV, there was a nonsignificant (p  0.07)
rend toward lower value in the cyclosporine group.
In each group, we noticed a nonsignificant decrease in
VEDV and LVESV between 5 days and 6 months.
There was a significant correlation between infarct size
nd both LVEDV (r2  0.40; p  0.05), LVESV (r2 
.66; p  0.05), and LVEF (r2  0.72; p  0.05) at 6
onths in the whole group of patients (Figs. 3 to 5).
Figure 2
Infarct Size (CMR 6 Months After Acute
Myocardial Infarction) as a Function of the Size
of the Area at Risk (LV Angiography at Admission)
There was a significant correlation between the 2 variables in the control group
(r2  0.84). Data points for the cyclosporine group (red squares) (r2  0.67)
lie below the regression line for the control group (blue circles). These data
indicate that, for any given area at risk, cyclosporine administration was asso-
ciated with a reduction in the resulting infarct size as measured by delayed
enhancement cardiac magnetic resonance (CMR). This difference was signifi-
cant by analysis of covariance (p  0.007). ACS  acute coronary syndrome;
LV  left ventricular; M6  6 months.
esults for Measures ofMR After 5 D ys and 6 MonthsTable 2 R sults for Measures ofCMR After 5 Days and 6 Months
Cyclosporine
(n  15)
Control
(n  13) p Value
After 5 days
LVEDV, ml 143 32 167 43 0.05
LVESV, ml 72 20 91 36 0.04
LVEF, % 50 10 47 11 0.19
Infarct size, g 34 14 48 24 0.03
After 6 months
LVEDV, ml 133 28 151 35 0.07
LVESV, ml 67 24 84 29 0.05
LVEF, % 51 9 46 11 0.10
Infarct size, g 29 15 38 14 0.04
alues are expressed as mean  SD.
CMR  cardiac magnetic resonance; LVEDV  left ventricular end-diastolic volume; LVEF  left
entricular ejection fraction; LVESV  left ventricular end-systolic volume.
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March 23, 2010:1200–5 Cyclosporine and LV RemodelingV regional wall thickness at 5 days and 6 months. We
ound no significant difference in global LV mass between
he 2 groups of patients at 5 days and 6 months (Table 3).
In the noninfarcted remote myocardium, there was no
ignificant effect of cyclosporine on end-diastolic or -systolic
all thickness at either 5 days or 6 months after infarction.
n both groups, there was a trend toward a moderate
ncrease in end-diastolic and -systolic wall thickness be-
ween 5 days and 6 months.
In the infarcted myocardium, there was no significant
ffect of cyclosporine on end-diastolic or -systolic wall
hickness at either 5 days or 6 months after infarction. In
oth groups, there was a trend toward a slight decrease in
nd-diastolic and -systolic wall thickness between 5 days
nd 6 months.
Figure 3 LVEDV as a Function of IS at 6 Months
There was a significant correlation between left ventricular end-diastolic volume
(LVEDV) and infarct size (IS) at 6 months (r2  0.40; p  0.05) in the whole
group of patients. Blue circles  control group; red squares  cyclosporine.
Abbreviations as in Figure 2.
Figure 4 LVESV as a Function of IS at 6 Months
There was a significant correlation between left ventricular end-systolic volume
(LVESV) and infarct size (IS) at 6 months (r2  0.66; p  0.05) in the whole
group of patients. Blue circles  control group; red squares  cyclosporine. aiscussion
he present study suggests that cyclosporine administered
n the acute phase of ST-segment elevation myocardial
nfarction before reperfusion does not have any detrimental
ffect on LV remodeling.
bsence of a detrimental effect of cyclosporine on LV
emodeling. AMI induces scar formation and global changes
n the surviving myocardium, designated as post-AMI ventric-
lar remodeling. The early hypertrophic remodeling of the
emote noninfarcted myocardium is considered an adaptive
esponse to preserve cardiac performance. One signaling path-
ay that links extracellular stimuli to a hypertrophic transcrip-
Figure 5 LVEF as a Function of IS 6 Months
After Myocardial Infarction
There was a significant correlation between left ventricular ejection fraction
(LVEF) and infarct size at 6 months (r2  0.72; p  0.05) in both groups.
Blue circles  control group; red squares  cyclosporine. Abbreviations as in
Figures 2 and 3.
eft Ventricular Wall Thickness in the Infarctedyocardium and in the Remote Nonischemict 5 Days and 6 Mo ths
Table 3
Left Ventricular Wall T ick ss in the Infarcted
Myocardium and in the Remote Nonischemic
Myocardium at 5 Days and 6 Months
Cyclosporine
(n  15)
Control
(n  13)
Infarcted myocardium, mm
After 5 days
EDWT 7.9 2.0 7.5 2.0
ESWT 8.7 2.8 8.2 2.9
After 6 months
EDWT 6.7 0.8 6.9 0.8
ESWT 7.3 0.6 8.1 0.8
Remote myocardium, mm
After 5 days
EDWT 8.0 1.4 8.4 1.9
ESWT 12.7 2.9 12.6 2.6
After 6 months
EDWT 8.8 0.5 9.3 0.6
ESWT 13.7 0.5 15.0 1.5
alues are expressed as mean  SD. There were no statistical differences between groups as
ssessed by 2-way analysis of variance (p  NS).
EDWT  end-diastolic wall thickness; ESWT  end-systolic wall thickness.
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Cyclosporine and LV Remodeling March 23, 2010:1200–5ional response of the myocyte uses the Ca2/calmodulin-
ependent phosphatase calcineurin and its downstream
ranscriptional effector nuclear factor of activated T cells.
yclosporine binds to the mitochondrial cyclophilin D and
hereby inhibits lethal reperfusion injury and reduces infarct
ize (2,3,9). However, cyclosporine also binds to the cytoso-
ic cyclophilin A and inhibits the calcium-activated protein
hosphatase calcineurin; it may therefore influence cardiac
ypertrophic response and LV remodeling after AMI. The
ffects of cyclosporine on immediate and long-term post–
yocardial infarction LV remodeling in animal experimen-
al models have been equivocal. In some studies, cyclospor-
ne was shown to impede the compensatory hypertrophy of
he remote noninfarcted myocardium, increase LV dilation,
nd decrease the myocardial systolic performance (7,8).
We showed that cyclosporine had no detrimental effect
n LV remodeling at 6 months. The regional modifications
f infarcted and noninfarcted myocardium were not differ-
nt between cyclosporine and control patients. This tends to
uggest that a single dose of cyclosporine was enough to
educe infarct size, but not sufficient to modify the
alcineurin-mediated hypertrophic response.
This apparent discordance between several experimen-
al studies and the present clinical study may be associ-
ted with different factors. First, all experimental studies
hat found a detrimental effect of cyclosporine used
epeated doses of this drug. In contrast, we used a single
ntravenous injection of cyclosporine. Second, we used a
.5-mg/kg dose, which was 4 to 10 times lower than that
sed in the previously mentioned studies. Third, the
iming of administration of cyclosporine differed greatly
mong all studies. Opening of the mitochondrial perme-
bility transition pore has been shown to occur in the
arly minutes of reperfusion and represents a “point of no
eturn” to cell death (10,11). Experimental studies using
schemic post-conditioning have shown that the time
indow to prevent lethal reperfusion injury is very narrow
fter reflow (12,13). This is the reason why cyclosporine
as injected before angioplasty of the culprit coronary
rtery in this clinical trial.
elationship between LV remodeling and persistent
nfarct size limitation by cyclosporine. At 6 months,
yclosporine–treated patients exhibited a 29% reduction of
rreversible myocardial damage, very similar to that observed
t 5 days (1). In previous studies, infarct size has been shown
o be a major prognostic factor, predictive of increased LV
emodeling, congestive heart failure, and clinical adverse
utcome. In recent studies, when assessed at 4 months and
p to 4 years, infarct size in multivariate analysis was one of
he strongest independent predictors of ejection fraction and
V volumes independently of scar localization and trans-
urality (14). Other studies assessing LV remodeling at
-month follow-up after AMI with echocardiography
howed that peak troponin T and peak creatine phosphoki-
ase levels, which are directly correlated with infarct size,
ere strong independent predictors of LV functional recov-ry (15,16). Thus, reducing the infarct size is an important
arget for the treatment of patients with ongoing acute
yocardial infarction. Together with a persistent reduction
f infarct size, we found that cyclosporine-treated patients
isplayed a significant attenuation of LVESV with a trend
oward a diminution of LVEDV enlargement. The small
umber of patients likely explains the nonsignificant im-
rovement of LVEF in the cyclosporine-treated patients
ompared with the control patients.
In the whole study population, the LV volumes and
VEF modifications followed patterns similar to those of
reviously published data in post-AMI LV remodeling
MR studies (14). Furthermore, we found comparable
orrelations between infarct size and LVEF, LVEDV, and
VESV with previously published data (17). The fact that
he cyclosporine and the control groups share the same
egression lines indicates that there was no specific effect of
yclosporine on LV remodeling and tells us that the
bserved trend toward improvement might be entirely due
o infarct size reduction (Figs. 3 to 5).
onclusions
his study shows that cyclosporine administered at the time
f AMI reperfusion does not have a detrimental effect on
V remodeling. On the contrary, cyclosporine seems to
ave a sustained beneficial effect on infarct size reduction,
hich might improve the post-infarction remodeling process.
hese results are preliminary and must be supported by further
tudies.
eprint requests and correspondence: Prof. Michel Ovize, In-
erm U886, Laboratoire de Physiologie Lyon-Nord, 8, avenue
ockefeller, 69373 Lyon, France. E-mail: Michel.ovize@recherche.
niv-lyon1.fr.
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